US specialty pharma business SERB Pharmaceuticals is acquiring Y-mAbs Therapeutics (Nasdaq: YMAB) in a $412 million all-cash ...

Japanese drugmaker Nxera Pharma has unveiled a slate of new programs targeting obesity and related metabolic diseases, ...

Shattuck Labs yesterday announced that it has entered into a securities purchase agreement for a private placement financing ...

The Russian government plans to increase procurements of drugs against hepatitis C due to a significant increase in the ...

The UK’s National Institute for Health and Care Excellence (NICE) on August 6 recommended the use of US pharma giant Merck & ...

US biotech major Amgen announced financial results for the second quarter of 2025 after market closed on Tuesday, with ...

A preclinical biotech company based in Wilmington, Delaware, focused on developing CAR‑T cell immunotherapies to treat severe ...

US cardiometabolic specialist MetaVia has announced a research collaboration with Korea’s Syntekabio, an artificial ...

Pfizer posted second-quarter 2025 earnings and revenue that exceeded analyst estimates and raised its full-year profit ...

Texas, USA-based Nanoscope Therapeutics has recently submitted a rolling biologics license application (BLA) to the Food and ...

Japanese drugmaker Sumitomo Pharma Company and Tokyo-based Racthera announced that on August 5, they had submitted an ...

Russia is currently experiencing a boom in the sales of Ozempic (semaglutide) and its analogues due to a high demand for such drugs among domestic customers, reports The Pharma Letter’s local ...